person · Reporting owner
SHROTRIYA RAJESH C MD
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avant Diagnostics, IncAVDX · Entity 148455 | Director | August 28, 2018 | September 14, 2018 |
| CASI Pharmaceuticals, Inc.CASI · Entity 123920 | Director | May 25, 2022 | May 26, 2022 |
| GT Biopharma, Inc.GTBP · Entity 7878 | Director | January 27, 2023 | February 01, 2023 |
| SPECTRUM PHARMACEUTICALS INCSPPI · Entity 111009 | Director | May 17, 2018 | May 17, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avant Diagnostics, Inc
Report date August 28, 2018 · Filed September 14, 2018
This filing explicitly reported no securities owned.
CASI Pharmaceuticals, Inc.
Report date May 25, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.47 · Expires 2032-05-25 | Direct | 345,806 |
Reported balance
After 2022-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-25 · Grant · Acquired 345,806 · Balance 345,806 F1: Stock option award will vest ratably quarterly to the end of the year. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option award will vest ratably quarterly to the end of the year.
GT Biopharma, Inc.
Report date January 27, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2033-01-26 | Direct | 500,000 |
Reported balance
After 2023-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-27 · Grant · Acquired 500,000 · Balance 500,000 F1: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct.
SPECTRUM PHARMACEUTICALS INC
Report date May 17, 2018 · Filed May 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 200,652 |
Ending reported balance
After 2018-05-17 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-05-17 · Exercise / conversion · Acquired 112,500 · Balance 313,152 Row 2 · 2018-05-17 · Exercise / conversion · Acquired 250,426 · Balance 563,578 Row 3 · 2018-05-17 · Gift · Disposed 362,926 · Balance 200,652 F1: Transfer for estate planning purposes by Reporting Person to the CS Family Trust. The Reporting Person has an indirect beneficial ownership as trustee of the CS Family Trust. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy CS Family Trust | 978,889 |
Reported balance
After 2018-05-17 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-05-17 · Gift · Acquired 362,926 · Balance 978,889 F1: Transfer for estate planning purposes by Reporting Person to the CS Family Trust. The Reporting Person has an indirect beneficial ownership as trustee of the CS Family Trust. |
| Stock Option Exercise (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2018-12-06 | Direct | 0 |
Reported balance
After 2018-05-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-05-17 · Exercise / conversion · Disposed 112,500 · Balance 0 |
| Stock Option Exercise (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2019-01-16 | Direct | 0 |
Reported balance
After 2018-05-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-05-17 · Exercise / conversion · Disposed 250,426 · Balance 0 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Shrotriya Gift Trust | 1,787,542 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,787,542 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy RS Irrevocable Trust | 1,243,284 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,243,284 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy 401(k) Plan | 28,907 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 28,907 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Spouse | 9,523 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 9,523 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Shrotriya Family Foundation | 67,144 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 67,144 |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy ROTH IRA | 40,000 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 40,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Transfer for estate planning purposes by Reporting Person to the CS Family Trust. The Reporting Person has an indirect beneficial ownership as trustee of the CS Family Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2023 Filed Feb 1, 2023 11:02 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-23-003226 · ownership.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:46 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 361,476 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019875 · ownership.xml · derivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,476 Underlying: Common Stock · 361,476 shares Expires 2032-07-14 F2 · derivative.exercise_date: 240,984 shares vest on the date of grant and 120,492 shares vest on January 13, 2023. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:46 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019875 · ownership.xml · derivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: 1/4th of the shares vest on the date of grant and on each of September 8, 2022, December 8, 2022 and March 8, 2023. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:46 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019875 · ownership.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-14 Read SEC document |
| May 25, 2022 Filed May 26, 2022 16:11 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 345,806 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-22-065264 · tm2214964d1_4.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,806 Underlying: Common Stock · 345,806 shares Expires 2032-05-25 F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:02 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 98.349 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001104659-21-081993 · tm2119809d4_4.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,349 Underlying: Common Stock · 98,349 shares Expires 2031-06-15 F1 · date: Stock option award will vest ratably quarterly to the end of the year. F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| February 16, 2021 Filed Feb 14, 2022 21:13 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001654954-22-001635 · section16.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-15 F1 · derivative.exercise_date: 1/3rd of the shares vest on February 16, 2021, 2022 and 2023. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 06:02 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 61,257 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001104659-20-074336 · tm2022841d1_form4.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,257 Underlying: Common Stock · 61,257 shares Expires 2030-06-16 F1 · date: Stock option award will vest ratably quarterly to the end of the year. F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 17:01 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Option (Right to Buy) · Derivative | 51,538 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001144204-19-031919 · tv524057_4.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,538 Underlying: Common Stock · 51,538 shares Expires 2029-06-20 F1 · date: Stock option award will vest ratably quarterly to the end of the year. F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of the year. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:30 UTC | CASI Pharmaceuticals, Inc. CASI · Entity 123920 | GrantStock Options (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $8.23 | $0.00 |
DisclosureSEC source: 0001144204-18-037308 · tv497978_4.xml · derivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-06-29 F1 · date: Stock option award will vest ratably quarterly to the end of one year. F1 · derivative.exercise_date: Stock option award will vest ratably quarterly to the end of one year. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Exercise / conversionStock Option Exercise (Right to Buy) · Derivative | 250,426 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001209191-18-031158 · doc4.xml · derivative · entry 12 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,426 shares Expires 2019-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Exercise / conversionStock Option Exercise (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-18-031158 · doc4.xml · derivative · entry 11 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,500 shares Expires 2018-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GiftCommon Stock, $0.001 par value | 362,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031158 · doc4.xml · nonDerivative · entry 4 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 978,889 F1 · kind: Transfer for estate planning purposes by Reporting Person to the CS Family Trust. The Reporting Person has an indirect beneficial ownership as trustee of the CS Family Trust. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GiftCommon Stock, $0.001 par value | 362,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031158 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,652 F1 · kind: Transfer for estate planning purposes by Reporting Person to the CS Family Trust. The Reporting Person has an indirect beneficial ownership as trustee of the CS Family Trust. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Exercise / conversionCommon Stock, $0.001 par value | 250,426 | $1.47 | $368,126.22 |
DisclosureSEC source: 0001209191-18-031158 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Exercise / conversionCommon Stock, $0.001 par value | 112,500 | $1.43 | $160,875.00 |
DisclosureSEC source: 0001209191-18-031158 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2018 Filed May 14, 2018 15:59 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 24,014 | $18.38 | $441,377.32 |
DisclosureSEC source: 0001209191-18-029809 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 615,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.075 to $18.50, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2018 Filed May 14, 2018 15:59 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.55 | $526,500.00 |
DisclosureSEC source: 0001209191-18-029809 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 639,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.81, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 10, 2018 Filed May 14, 2018 15:59 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.13 | $513,900.00 |
DisclosureSEC source: 0001209191-18-029809 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 669,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.25, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 09, 2018 Filed May 9, 2018 16:02 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.21 | $486,300.00 |
DisclosureSEC source: 0001209191-18-028834 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 699,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.09 to $16.30, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 08, 2018 Filed May 9, 2018 16:02 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.11 | $483,300.00 |
DisclosureSEC source: 0001209191-18-028834 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 729,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.99 to $16.20, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 07, 2018 Filed May 9, 2018 16:02 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $15.98 | $479,400.00 |
DisclosureSEC source: 0001209191-18-028834 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 759,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.61 to $16.39, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 04, 2018 Filed May 4, 2018 15:37 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.79 | $503,700.00 |
DisclosureSEC source: 0001209191-18-028053 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 789,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.25 to $17.05, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 03, 2018 Filed May 4, 2018 15:37 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.01 | $480,300.00 |
DisclosureSEC source: 0001209191-18-028053 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 819,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.72 to $16.10, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 02, 2018 Filed May 4, 2018 15:37 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.04 | $481,200.00 |
DisclosureSEC source: 0001209191-18-028053 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 849,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.179, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 01, 2018 Filed May 1, 2018 17:55 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $15.77 | $473,100.00 |
DisclosureSEC source: 0001209191-18-027180 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 879,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $16.00, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 30, 2018 Filed May 1, 2018 17:55 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.36 | $490,800.00 |
DisclosureSEC source: 0001209191-18-027180 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 909,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.15 to $16.60, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 27, 2018 Filed May 1, 2018 17:55 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.17 | $515,100.00 |
DisclosureSEC source: 0001209191-18-027180 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 939,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.63 to $17.30, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 26, 2018 Filed Apr 26, 2018 18:39 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.26 | $517,800.00 |
DisclosureSEC source: 0001209191-18-026312 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 969,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $17.33, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:39 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.26 | $517,800.00 |
DisclosureSEC source: 0001209191-18-026312 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 999,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.42, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 18:39 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $18.11 | $543,300.00 |
DisclosureSEC source: 0001209191-18-026312 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,029,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.93 to $18.40, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 23, 2018 Filed Apr 23, 2018 21:53 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $18.37 | $551,100.00 |
DisclosureSEC source: 0001209191-18-025910 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,059,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.60, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 21:53 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $18.67 | $560,100.00 |
DisclosureSEC source: 0001209191-18-025910 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,089,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.41 to $18.80, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2018 Filed Apr 23, 2018 21:53 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $19.18 | $575,400.00 |
DisclosureSEC source: 0001209191-18-025910 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,119,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.43, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2018 Filed Apr 18, 2018 16:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $19.71 | $591,300.00 |
DisclosureSEC source: 0001209191-18-025379 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,149,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.51 to $20.08, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 16:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $18.56 | $556,800.00 |
DisclosureSEC source: 0001209191-18-025379 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,179,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.49 to $18.62, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 16:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $18.72 | $561,600.00 |
DisclosureSEC source: 0001209191-18-025379 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,209,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.41 to $19.20, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 17:07 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $19.93 | $597,900.00 |
DisclosureSEC source: 0001209191-18-024860 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,239,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $20.49, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 17:07 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $20.72 | $621,600.00 |
DisclosureSEC source: 0001209191-18-024860 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,269,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.80, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 17:07 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $20.30 | $609,000.00 |
DisclosureSEC source: 0001209191-18-024860 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,299,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.97 to $21.00, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 10, 2018 Filed Apr 10, 2018 20:41 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.74 | $532,200.00 |
DisclosureSEC source: 0001209191-18-024576 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,329,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.49 to $17.90, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 09, 2018 Filed Apr 10, 2018 20:41 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 12,300 | $15.01 | $184,623.00 |
DisclosureSEC source: 0001209191-18-024576 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,359,977 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.03, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 20:41 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 3,686 | $15.00 | $55,290.00 |
DisclosureSEC source: 0001209191-18-024576 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,372,277 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. Read SEC document |
| April 05, 2018 Filed Apr 5, 2018 16:00 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $15.33 | $459,900.00 |
DisclosureSEC source: 0001209191-18-024021 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,375,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.07 to $15.96, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 04, 2018 Filed Apr 5, 2018 16:00 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $15.01 | $450,300.00 |
DisclosureSEC source: 0001209191-18-024021 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,405,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.02, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:00 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $15.14 | $454,200.00 |
DisclosureSEC source: 0001209191-18-024021 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,435,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.03 to $15.26, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 02, 2018 Filed Apr 2, 2018 17:43 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $15.61 | $468,300.00 |
DisclosureSEC source: 0001209191-18-022545 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,465,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $16.20, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 17:43 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.18 | $485,400.00 |
DisclosureSEC source: 0001209191-18-022545 · doc4.xml · nonDerivative · entry 1 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,495,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.37, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 28, 2018 Filed Mar 28, 2018 16:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $16.19 | $485,700.00 |
DisclosureSEC source: 0001209191-18-021929 · doc4.xml · nonDerivative · entry 3 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,525,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.76 to $16.40, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 16:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 30,000 | $17.10 | $513,000.00 |
DisclosureSEC source: 0001209191-18-021929 · doc4.xml · nonDerivative · entry 2 SHROTRIYA RAJESH C MD · CIK 0001193918 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CS Family Trust Disclosed balance after: 1,555,963 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.61 to $17.88, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.